September 29, 2009

Division of Dockets Management  
HFA-305  
Food and Drug Administration  
5630 Fishers Lane, Room 1061  
Rockville, MD 20852

Re: Docket No. FDA-2009-N-0294

Dear Sir/Madam:

The American Association for Cancer Research (AACR), with over 29,000 members, is the oldest and largest scientific organization in the world dedicated to the prevention and cure of cancer through research, education, communication, and collaboration. We appreciate the opportunity to provide comments in response to the U.S. Food and Drug Administration’s (FDA) notice on the Regulation of Tobacco Products.

As we have known for many years, tobacco use is the leading preventable cause of premature mortality, killing more than 5 million people worldwide every year. Tobacco use has a particularly profound impact on cancer incidence and mortality. Indeed, tobacco use is causally associated with 15 different cancers, including lung, head and neck, stomach, pancreas, and cervical cancers, and alone tobacco accounts for 30% of all cancer deaths. The AACR Task Force on Tobacco and Cancer was convened to foster scientific and policy initiatives to reduce the incidence of disease and mortality due to tobacco use.

Given that tobacco use has been definitively proven to cause cancer, the AACR has a keen interest in strategic priorities that the FDA will pursue under the new regulatory authority over tobacco products granted by the Family Smoking Prevention and Tobacco Control Act (FSPTCA). The AACR appreciates the opportunity to participate in the planning for implementation of the FSPTCA and looks forward to future opportunities to provide comments and information as the rulemaking process progresses. Our recommendations below are based on three fundamental premises: (1) there is no known safe form of tobacco; (2) reduction of the morbidity and mortality from tobacco use to the greatest extent possible should be the FDA’s goal; and (3) those with interest in sustaining tobacco use will strive to undermine the intent of the legislation.
Given these premises, the AACR makes the following recommendations regarding implementation of the legislation:

1. Develop and implement a plan to reduce delivered amounts of nicotine or other addicting constituents in tobacco products to levels that do not sustain addiction to these products. In addition, to the extent identified by science, modifications of tobacco product design that are proven to reduce addiction potential should be implemented. Reduction of the addicting agents in tobacco to levels that are not addicting to anyone would stop the progression from experimentation with tobacco products to regular use to addiction.

2. Remove, as rapidly as possible, menthol from tobacco products. Most other flavorings have been removed, and menthol should be as well. Mentholized cigarettes are used by a large majority of African American smokers, and there is evidence that menthol helps to sustain tobacco use, in part by making tobacco smoke more palatable. Elimination of menthol will make quitting tobacco less difficult for those who find menthol reinforcing.

3. In collaboration with the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH), develop and implement a national surveillance system to track tobacco products and tobacco use with the goal of using the data to serve as an early warning system to track new tobacco products and populations who use them—much as new communicable diseases are tracked.

4. Require stringent and effective warning labels for tobacco products based on scientific evidence.

5. Require that the regulation and labeling of tobacco products be more stringent than that of tobacco use treatments, including nicotine replacement products (NRT), in proportion to the relative harm of these two classes of products.

6. Implement fast track review and approval of tobacco cessation products, and actively lead an initiative to increase tobacco treatment medication development, taking into account genetic, behavioral, and environmental factors, and medication accessibility that is akin to the initiatives that led to dramatic improvements in HIV/AIDS treatment. Develop a coordinated tobacco control effort between the FDA (e.g., in collaboration with the Center for Drug Evaluation and Research) and other government agencies (e.g., NIH, Agency for Healthcare Research and Quality, and Centers for Medicare and Medicaid Services) and the private sector to address this priority.

7. Require that all tobacco product labels include the national toll free quitline number (1-800-QUITNOW), and provide resources to NIH and CDC to test new forms of treatment and increase the national infrastructures (e.g., quitlines) needed to treat more tobacco addicted Americans.
8. In fulfilling obligations under Section 918 of the FSPTCA, act on promoting tobacco cessation to meet the Healthy People 2010 goal to reduce and eliminate health disparities; foster research to understand how tobacco company marketing targets populations; better identify the risk factors for initiation and disease risk among different population groups; develop better methods to promote cessation; and develop better methods to inform the public of the risks of tobacco use.

9. Establish a comprehensive framework for the evaluation of new tobacco products prior to their introduction into the marketplace. We recognize that current research gaps will create early limitations as the FDA implements this framework, and so FDA should fund areas of research gaps that preclude full implementation of the framework.

10. Establish a comprehensive framework for the evaluation of manufacturer's health claims for modified tobacco products, which may overlap with a framework to evaluate all new tobacco products. The evaluation of manufacturer's health claims will need to be assessed by human studies of sufficient size, scope, and duration. Research gaps may currently preclude the substantiation of any manufacturer's claims at this time, and so FDA should fund areas of research gaps that prevent full implementation of the framework.

11. Issue a regulation to deem all tobacco products, including cigars, pipe tobacco, and waterpipe tobacco, subject to the FSPTCA; prohibit these products from having candy, fruit, and spice flavors as characterizing flavors; apply all tobacco package labeling requirements to these products; and apply to these products the youth access and advertising and promotion restrictions of the regulations promulgated in the August 28, 1996, issue of the Federal Register (61 Fed. Reg., 44615-44618).

12. Act to reduce exposure by youth to smoking in media, including motion pictures, through regulatory changes where possible.

13. Support the research of, and issue warnings related to, the toxic effects of tobacco residue in fabrics, upholstery, and air.

14. Ban the sale of gum, candy, or other food products that are designed and packaged to mimic tobacco products. Such products constitute tobacco marketing that appeals to children.

15. Require that the safety and efficacy of any alternative nicotine or tobacco delivery system, including the so-called electronic cigarettes, be established before being marketed or sold in the USA.
The AACR Task Force on Tobacco and Cancer, the full roster of which is enclosed for your information, is willing and able to provide expert information as the FDA implements this critical new law. The AACR stands with the FDA in its efforts to eliminate tobacco use, and its members are prepared to work with the FDA and other partners to make that happen in our lifetime.

Sincerely,

Roy S. Herbst, M.D., Ph.D.
Chair, Task Force on Tobacco and Cancer

William S. Dalton, Ph.D., M.D.
Chair, Science Policy and Legislative Affairs Committee

Tyler Jacks, Ph.D.
President

Margaret Foti, Ph.D., M.D. (h.c.)
Chief Executive Officer

Enclosure
2009 TASK FORCE ON TOBACCO AND CANCER

Roy S. Herbst, M.D., Ph.D., Chairperson
Barnhart Family Distinguished Professor of Targeted Therapy
Chief, Section of Thoracic Medical Oncology
Department of Thoracic/Head and Neck Medical Oncology
The University of Texas M. D. Anderson Cancer Center

Scott J. Leischow, Ph.D.
Associate Director, Behavioral and Social Sciences Research Program
Arizona Cancer Center
Professor, Colleges of Medicine and Public Health
The University of Arizona

Thomas H. Brandon, Ph.D.
Professor, Psychology & Oncologic Sciences
University of South Florida
Director, Tobacco Research and Intervention Program
H. Lee Moffitt Cancer Center & Research Institute

John D. Minna, M.D.
Director
Hamon Center for Therapeutic Oncology Research
Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology
Sarah M. And Charles E. Seay Distinguished Chair in Cancer Research
University of Texas Southwestern Medical Center

Michael C. Fiore, M.D., MPH, MBA
Professor of Medicine
Director, Center for Tobacco Research and Intervention
School of Medicine and Public Health
University of Wisconsin

Peter G. Shields, M.D.
Professor of Medicine and Oncology
Deputy Director, Lombardi Comprehensive Cancer Center
Georgetown University Medical Center

Ellen R. Gritz, Ph.D.
Professor and Chair
Department of Behavioral Science
Olla S. Stribling Distinguished Chair for Cancer Research
The University of Texas M. D. Anderson Cancer Center

David Sidransky, M.D.
Professor of Oncology, Pathology and Cellular and Molecular Medicine
Director of Head and Neck Research
Johns Hopkins Medical Institute

Stephen S. Hecht, Ph.D.
Wallin Professor of Cancer Prevention
Department of Medicinal Chemistry
University of Minnesota

Kasisomayajula (Vish) Viswanath, Ph.D.
Associate Professor
Department of Society, Human Development, and Health
Harvard School of Public Health
Associate Professor of Population Sciences
Department of Medical Oncology
Dana-Farber Cancer Institute

Stephanie R. Land, Ph.D.
Research Associate Professor
Director, ReSET Center
Department of Biostatistics
Graduate School of Public Health
NSABP and University of Pittsburgh Cancer Institute
University of Pittsburgh